Publications by authors named "Chaohsuan Pan"

Article Synopsis
  • The study aimed to create a population pharmacokinetics (PopPK) model for sugemalimab, a PD-L1 targeting monoclonal antibody, using data from multiple clinical trials to understand factors affecting drug exposure.
  • A nonlinear mixed-effect modelling approach analyzed data from 1628 subjects across nine studies, assessing how different characteristics like demographics and health conditions impacted sugemalimab pharmacokinetics.
  • The final model showed that body weight, albumin, gender, and tumor characteristics significantly influenced drug clearance, though none of these covariates had a clinically meaningful effect on overall sugemalimab exposure, suggesting no need for dose adjustments based on these factors.
View Article and Find Full Text PDF

Purpose: This study aimed to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of ivosidenib in Chinese patients with relapsed or refractory acute myeloid leukemia (R/R AML) carrying the mIDH1 mutation.

Methods: A bridging study (NCT04176393) was conducted involving 29 Chinese patients who received a daily dose of ivosidenib 500 mg in 28-day cycles. Plasma concentrations of ivosidenib and D-2-hydroxyglutarate (2-HG) were measured before and after treatment.

View Article and Find Full Text PDF

Targeted combination chemotherapy (TCT) has recently been used to increase the induction of tumor cell death. In particular, the combination of Panitumumab and the platinum (Pt)-derived chemotherapeutic drug Oxaliplatin is clinically effective against KRAS and BRAF wild-type colorectal cancer (CRC) cells that overexpress epidermal growth factor receptors, and significantly greater efficacy is observed than with either drug alone. However, low accumulation of Pt drug in tumor sites prevents achievement of ideal efficacy.

View Article and Find Full Text PDF